Ductal Carcinoma In Situ

Surg Clin North Am. 2018 Aug;98(4):725-745. doi: 10.1016/j.suc.2018.03.007. Epub 2018 May 28.


Ductal carcinoma in situ has been stable in incidence for a decade and has an excellent prognosis. Breast conservation therapy is safe and effective for most patients. Adjuvant whole breast radiation therapy is recommended to reduce the risk of local recurrence. Accelerated partial breast irradiation is a promising alternative to decrease toxicity and improve cosmetic results. Adjuvant hormonal therapy can reduce local recurrence, but should be used cautiously. Future directions in management include developing predictive tools for guidance for use of adjuvant therapy and selecting low-risk patients with ductal carcinoma in situ in whom surgery may be safely omitted.

Keywords: Breast cancer; Ductal carcinoma in situ; Hormonal therapy; Incidence; Mortality; Radiation therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / therapy*
  • Carcinoma, Intraductal, Noninfiltrating / diagnosis*
  • Carcinoma, Intraductal, Noninfiltrating / epidemiology
  • Carcinoma, Intraductal, Noninfiltrating / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Mastectomy, Segmental
  • Patient Selection


  • Antineoplastic Agents, Hormonal